Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations

Santos, 2016, Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel, Lancet Diabetes Endocrinol, 4, 850, 10.1016/S2213-8587(16)30041-9 Nordestgaard, 2013, Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society, Eur Heart J, 34, 3478, 10.1093/eurheartj/eht273 Sjouke, 2015, Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome, Eur Heart J, 36, 560, 10.1093/eurheartj/ehu058 Hopkins, 2015, Characterization of autosomal dominant hypercholesterolemia caused by PCSK9 gain of function mutations and its specific treatment with alirocumab, a PCSK9 monoclonal antibody, Circ Cardiovasc Genet, 8, 823, 10.1161/CIRCGENETICS.115.001129 Defesche, 2017, Familial hypercholesterolaemia, Nat Rev Dis Primers, 3, 17093, 10.1038/nrdp.2017.93 Andersen, 2016, Familial defective apolipoprotein B-100: a review, J Clin Lipidol, 10, 1297, 10.1016/j.jacl.2016.09.009 Sjouke, 2015, Homozygous autosomal dominant hypercholesterolaemia: prevalence, diagnosis, and current and future treatment perspectives, Curr Opin Lipidol, 26, 200, 10.1097/MOL.0000000000000179 Borén, 2001, The molecular mechanism for the genetic disorder familial defective apolipoprotein B100, J Biol Chem, 276, 9214, 10.1074/jbc.M008890200 Shapiro, 2018, PCSK9: from basic science discoveries to clinical trials, Circ Res, 122, 1420, 10.1161/CIRCRESAHA.118.311227 Seidah, 2014, PCSK9: a key modulator of cardiovascular health, Circ Res, 114, 1022, 10.1161/CIRCRESAHA.114.301621 Horton, 2009, PCSK9: a convertase that coordinates LDL catabolism, J Lipid Res, 50, S172, 10.1194/jlr.R800091-JLR200 Stein, 2012, Effect of a monoclonal antibody to PCSK9 on LDL cholesterol, N Engl J Med, 366, 1108, 10.1056/NEJMoa1105803 Seidah, 2017, The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol, Glob Cardiol Sci Pract, 2017, e201702 Roth, 2014, Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody, Future Cardiol, 10, 183, 10.2217/fca.13.107 Rey, 2016, Relationship between low-density lipoprotein cholesterol, free proprotein convertase subtilisin/kexin type 9, and alirocumab levels after different lipid-lowering strategies, J Am Heart Assoc, 5, e003323, 10.1161/JAHA.116.003323 Reyes-Soffer, 2017, Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans, Circulation, 135, 352, 10.1161/CIRCULATIONAHA.116.025253 Giunzioni, 2015, New developments in atherosclerosis: clinical potential of PCSK9 inhibition, Vasc Health Risk Manag, 11, 493 Glerup, 2017, Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease, Basic Res Cardiol, 112, 32, 10.1007/s00395-017-0619-0 Abifadel, 2014, Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs, Curr Atheroscler Rep, 16, 439, 10.1007/s11883-014-0439-8 Friedewald, 1972, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge, Clin Chem, 18, 499, 10.1093/clinchem/18.6.499 Defesche, 2017, Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia, J Clin Lipidol, 11, 1338, 10.1016/j.jacl.2017.08.016 Raal, 2015, Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial, Lancet, 385, 341, 10.1016/S0140-6736(14)61374-X Hartgers, 2018, Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia, J Clin Lipidol, 12, 390, 10.1016/j.jacl.2017.12.008 Kastelein, 2015, ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia, Eur Heart J, 36, 2996 McKenney, 2012, Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy, J Am Coll Cardiol, 59, 2344, 10.1016/j.jacc.2012.03.007 Brown, 2018, Retrospective on cholesterol homeostasis: the central role of Scap, Annu Rev Biochem, 87, 783, 10.1146/annurev-biochem-062917-011852 Tavori, 2015, On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects, Atherosclerosis, 238, 264, 10.1016/j.atherosclerosis.2014.12.017 Soria, 1989, Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100, Proc Natl Acad Sci U S A, 86, 587, 10.1073/pnas.86.2.587 Guo, 2014, PCSK9 and lipid lowering drugs, Clin Chim Acta, 437, 66, 10.1016/j.cca.2014.07.008 Mayne, 2008, Plasma PCSK9 levels are significantly modified by statins and fibrates in humans, Lipids Health Dis, 7, 22, 10.1186/1476-511X-7-22 Cunningham, 2007, Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia, Nat Struct Mol Biol, 14, 413, 10.1038/nsmb1235 Roth, 2012, Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia, N Engl J Med, 367, 1891, 10.1056/NEJMoa1201832 Gaudet, 2017, Effect of alirocumab on lipoprotein(a) over >/=1.5 years (from the Phase 3 ODYSSEY program), Am J Cardiol, 119, 40, 10.1016/j.amjcard.2016.09.010